SV Health’s $269M dementia fund; Schrödinger lays off 7% of staffnews2025-05-20T14:24:54+00:00May 20th, 2025|Endpoints News|
Ionis details late-stage data for heart drug; Armata’s promising staph infection therapynews2025-05-19T14:21:37+00:00May 19th, 2025|Endpoints News|
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approvalnews2025-05-16T14:25:07+00:00May 16th, 2025|Endpoints News|
Enliven stops work on solid tumor drug; Pulmatrix to divest assetsnews2025-05-15T14:46:10+00:00May 15th, 2025|Endpoints News|
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39Mnews2025-05-14T15:08:18+00:00May 14th, 2025|Endpoints News|
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit dealnews2025-05-13T14:40:32+00:00May 13th, 2025|Endpoints News|
FDA clears in vivo blood stem cell editing trial; Abeona’s $155M PRV salenews2025-05-12T14:34:12+00:00May 12th, 2025|Endpoints News|
Sanofi scraps IGM deal; Lilly to pay $250M to continue work with Purdue Universitynews2025-05-09T15:20:04+00:00May 9th, 2025|Endpoints News|
ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffsnews2025-05-08T15:04:16+00:00May 8th, 2025|Endpoints News|
NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degradernews2025-05-07T14:59:33+00:00May 7th, 2025|Endpoints News|
